Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 11 November 2020. Grady Hannah.

Executive Summary

The US FDA has authorized Nightware, a digital therapeutic that helps reduce sleep disruption in patients with PTSD or nightmare disorder. Nightware Inc. CEO Grady Hannah praised the move.

“In addition to a lack of approved treatment for PTSD-associated nightmares, the FDA’s blessing establishes that this is a serious public health issue and confirms the clinical benefit at a low level of risk for users.” – Grady Hannah, CEO, Nightware Inc.

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts